MedTrace Logo

Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection

NCT04750330 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 394

Last updated 2023-06-15

No results posted yet for this study

Summary

In December 2019, the first people got infected with COVID-19 in Wuhan, China. Within weeks, this highly infectious disease spread all over the world. Nearly one year later everyone is still trying to battle this disease and facing the consequences it causes. What became clear is that the disease and its severity differs largely between infected people. However, knowledge about who will experience severe COVID-19 and who does not is still unclear. Therefore, the aim of this study is to investigate the prognostic value of certain parameters (mtDNA and CT radiomics signature) for the severity of COVID-19.

Conditions

  • Covid19

Sponsors & Collaborators

  • Innovative Medicines Initiative

    collaborator OTHER

  • Maastricht University

    lead OTHER

Principal Investigators

  • Philippe Lambin, Prof. Dr. · Head of Department of Precision Medicine, Maastricht University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-06-12
Completion
2023-06-12

Countries

  • Greece
  • Italy
  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750330 on ClinicalTrials.gov